ExpreS2ion's Patent Application for Xylosylated N-Glycan Technology Published in the United States

Hørsholm, Denmark, 6 July 2026 – ExpreS2ion Biotech Holding AB's affiliate ExpreS2ion Biotechnologies ApS ("ExpreS2ion"), a clinical-stage biotechnology company with a pipeline of novel immunotherapies targeting oncology and infectious diseases, today announces the publication of its patent application titled "Recombinant Production of Protein Having Xylosylated N-Glycans" by the United States Patent and Trademark Office (USPTO).

The application (US 2026/0184752 A1) describes recombinant production methods enabling controlled incorporation of xylosylated N-glycans into complex protein antigens, leveraging ExpreS2ion's proprietary *Drosophila* S2-based expression technologies. The application had previously been published by the Hong Kong Intellectual Property Department in April 2026. Publication in the United States extends the geographic reach of this IP position into one of the company's largest addressable markets for licensing and partnering.

The patent application includes data showing that xylosylation of the SARS-CoV-2 receptor-binding domain (RBD) increased antibody titres in mice compared to the non-xylosylated protein, both as a soluble antigen and when displayed on virus-like particles.

Highlights

- Extends ExpreS2ion's glyco-engineering IP position to the United States, one of the company's largest addressable markets.
- Application includes mouse immunogenicity data showing higher antibody titres for xylosylated RBD antigen compared to non-xylosylated RBD.
- Broad claim scope covers antigen targets across oncology (VAR2CSA, HER2) and infectious disease (including SARS-CoV-2, influenza, HIV, CMV, and multiple other pathogens).

Bent U. Frandsen, CEO of ExpreS2ion, comments
"Publication in the United States is an important step in securing broad protection for our glyco-engineering technology in one of our key target markets. The data included in this application, showing improved antibody responses with xylosylated antigens, reinforces the commercial and scientific case for this platform."

Dr. Max M. Soegaard, CSO of ExpreS2ion, comments
"The immunogenicity data in this application, comparing xylosylated and non-xylosylated RBD antigen in mice, gives us a concrete demonstration of how this glyco-engineering approach can improve vaccine and immunotherapy performance. This supports our ambition to develop best-in-class immunotherapies and vaccines using the ExpreS2 platform."

Next Steps
Following publication, the application will proceed through standard USPTO examination. ExpreS2ion will communicate updates as the patent advances toward subsequent procedural milestones.

About glycoengineering in *Drosophila* S2 cells and the prospects
By modifying specific biochemical pathways in our *Drosophila* S2 cell lines, we enable them to alter the surface properties of the proteins they produce. These modifications can significantly enhance the immune response to a protein, making the resulting immunotherapy or vaccine much more effective while also reducing production costs. We are continually developing these GlycoX-S2 cell lines to further refine the ExpreS2™ system's full potential for creating novel biologics.

Certified Adviser
Redeye Nordic Growth AB

The information was sent for publication, through the agency of the contact persons set out above, at the time stated by the Company's news distributor, MFN, at the publication of this press release.

For further information about ExpreS2ion, please contact:
Bent U. Frandsen, CEO
Keith Alexander, CFO
Email: investor@expres2ionbio.com

About ExpreS2ion
ExpreS2ion is a biotechnology company focused on the development of innovative active immunotherapies and vaccines for cancer and infectious diseases. The company has developed the ExpreS2™ platform, a proprietary protein expression technology used across more than 500 recombinant protein and virus-like particle (VLP) projects spanning research, diagnostics, and therapeutic development. Proteins produced using the ExpreS2 platform are being evaluated in multiple clinical programmes worldwide. The platform has also been applied in partnered development programmes that have progressed into late-stage clinical evaluation, including Phase III studies that have met their primary endpoints. The platform, marketed as GlycoX-S2™, includes functionally modified glycosylation variants designed to enhance immunogenicity and pharmacokinetics. ExpreS2ion develops novel VLP-based vaccines in association with AdaptVac ApS, of which ExpreS2ion owns 34%. ExpreS2ion Biotech AB is listed on Nasdaq First North Growth Market. For additional information, please visit www.expres2ionbio.com.

Image Attachments
DSC 0498 Just